IN2015DN04310A - - Google Patents

Info

Publication number
IN2015DN04310A
IN2015DN04310A IN4310DEN2015A IN2015DN04310A IN 2015DN04310 A IN2015DN04310 A IN 2015DN04310A IN 4310DEN2015 A IN4310DEN2015 A IN 4310DEN2015A IN 2015DN04310 A IN2015DN04310 A IN 2015DN04310A
Authority
IN
India
Prior art keywords
vsli
contamination
disclosed
intravenous injection
improved methods
Prior art date
Application number
Other languages
English (en)
Inventor
William T Monte
Christopher James Barbosa
Thomas Philip Weber
Original Assignee
Spectrum Pharmaceuticals
Tekmira Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spectrum Pharmaceuticals, Tekmira Pharmaceuticals Corp filed Critical Spectrum Pharmaceuticals
Publication of IN2015DN04310A publication Critical patent/IN2015DN04310A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN4310DEN2015 2012-11-20 2013-11-20 IN2015DN04310A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728378P 2012-11-20 2012-11-20
PCT/US2013/071096 WO2014081887A1 (en) 2012-11-20 2013-11-20 Improved method for the preparation of liposome encapsulated vincristine for therapeutic use

Publications (1)

Publication Number Publication Date
IN2015DN04310A true IN2015DN04310A (ja) 2015-10-16

Family

ID=49885379

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4310DEN2015 IN2015DN04310A (ja) 2012-11-20 2013-11-20

Country Status (14)

Country Link
US (1) US9801874B2 (ja)
EP (2) EP3470061A1 (ja)
JP (1) JP6419710B2 (ja)
KR (2) KR102310697B1 (ja)
CN (1) CN104837483B (ja)
AU (1) AU2013347990B2 (ja)
CA (1) CA2891656C (ja)
ES (1) ES2730405T3 (ja)
IL (1) IL238555B (ja)
IN (1) IN2015DN04310A (ja)
MX (1) MX2015005992A (ja)
RU (1) RU2655964C2 (ja)
TR (1) TR201908531T4 (ja)
WO (1) WO2014081887A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470061A1 (en) 2012-11-20 2019-04-17 Spectrum Pharmaceuticals, Inc. Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
TWI719105B (zh) * 2016-01-04 2021-02-21 中央硏究院 基於酯化/皂化用於微脂體負載之方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2932718A (en) * 1957-06-25 1960-04-12 Thomas D Kinney Test tube warmer
US3115861A (en) 1960-02-29 1963-12-31 J L Tremper Locating elements of construction beneath the surface of earth soils
US3581703A (en) 1969-04-28 1971-06-01 Robert C Hosack Warning tape for underground installations
US3718113A (en) 1970-07-13 1973-02-27 Minnesota Mining & Mfg Buried pipeline signal
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
CA1260393A (en) 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US5622713A (en) 1985-09-17 1997-04-22 The Regents Of The University Of California Method of detoxifying animal suffering from overdose
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5755788A (en) 1987-02-19 1998-05-26 Rutgers, The State University Prosthesis and implants having liposomes bound thereto and methods of preparation
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
US5262168A (en) 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
US4952408A (en) 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
CA2056435A1 (en) 1989-05-15 1990-11-16 Thomas D. Madden Accumulation of drugs into liposomes by a proton gradient
AU6428890A (en) 1989-09-12 1991-04-18 Regents Of The University Of California, The Therapeutic peptides and proteins
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
ATE194767T1 (de) 1992-03-23 2000-08-15 Univ Georgetown In liposomen verkapseltes taxol und verwendungsverfahren
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
GB9304745D0 (en) 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5417978A (en) 1993-07-29 1995-05-23 Board Of Regents, The University Of Texas System Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use
EP0721328A4 (en) 1993-09-27 1997-09-17 Smithkline Beecham Corp CAMPTOTHECIN FORMULATIONS
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
US6855331B2 (en) 1994-05-16 2005-02-15 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5543152A (en) 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
IL115099A (en) 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5972379A (en) 1995-02-14 1999-10-26 Sequus Pharmaceuticals, Inc. Liposome composition and method for administering a quinolone
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
EP0832271B8 (en) 1995-06-07 2005-03-02 INEX Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0949906A4 (en) 1996-10-22 2004-11-24 Hermes Biosciences Inc LIPOSOMES LOADED WITH ACTIVE SUBSTANCE AND THEIR PRODUCTION METHOD
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
BR9812316A (pt) 1997-09-16 2001-03-20 Nexstar Pharmaceuticals Inc Formulações de camptotecina lipossÈmica
US6740335B1 (en) 1997-09-16 2004-05-25 Osi Pharmaceuticals, Inc. Liposomal camptothecin formulations
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
ATE238039T1 (de) 1998-09-16 2003-05-15 Alza Corp In liposomen eingeschlossene topoisomerase inhibitoren
US5991013A (en) 1998-10-27 1999-11-23 At&T Corp. Conveyance warning member with sacrificial fiber
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US7311924B2 (en) 1999-04-01 2007-12-25 Hana Biosciences, Inc. Compositions and methods for treating cancer
US7244450B2 (en) 1999-04-01 2007-07-17 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
EP1114839A4 (en) 1999-05-20 2002-09-25 Daicel Chem POLYESTER DIOL, POLYURETHANE OBTAINED FROM SAID DIOL AND SPANDEX FILAMENT THEREOF, AND NEW ACRYLIC COPOLYMER CONTAINING DIALKYLAMINO, POLYESTER COMPOSITION AND SPANDEX COMPOSITION
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US7094423B1 (en) 1999-07-15 2006-08-22 Inex Pharmaceuticals Corp. Methods for preparation of lipid-encapsulated therapeutic agents
US6352996B1 (en) 1999-08-03 2002-03-05 The Stehlin Foundation For Cancer Research Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin
US7452550B2 (en) 2000-06-30 2008-11-18 Hana Biosciences, Inc. Liposomal antineoplastic drugs and uses thereof
ES2253398T3 (es) 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. Camptotecinas liposomales mejoradas y sus usos.
AU2002214649A1 (en) 2000-10-16 2002-04-29 Neopharm, Inc. Liposomal formulation of mitoxantrone
US6825206B1 (en) 2000-11-16 2004-11-30 Research Triangle Institute Camptothecin compounds with a thioether group
CA2430947A1 (en) * 2000-12-08 2002-06-13 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
US6653319B1 (en) 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
DE60237162D1 (de) 2001-10-03 2010-09-09 Celator Pharmaceuticals Inc Liposomenladung mit metallionen
JP4555569B2 (ja) 2001-11-13 2010-10-06 セレーター ファーマシューティカルズ， インコーポレイテッド 増強された血中安定性を有する脂質キャリア組成物
US6627614B1 (en) 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
JP4245384B2 (ja) 2003-03-18 2009-03-25 株式会社ヤクルト本社 カンプトテシン類含有医薬組成物
EP1643972A4 (en) 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
US20050129750A1 (en) 2003-12-15 2005-06-16 Yu-Fang Hu Process for producing liposome suspension and product containing liposome suspension produced thereby
KR101376895B1 (ko) 2004-05-03 2014-03-25 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
DE602005018043D1 (de) 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
US7449196B2 (en) 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
ATE545408T1 (de) 2004-08-10 2012-03-15 Talon Therapeutics Inc Zusammensetzungen und verfahren zur behandlung von leukämie
CA2584279C (en) 2004-11-05 2015-01-27 Index Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
CN100356920C (zh) * 2004-12-27 2007-12-26 北京文卓医药生物制品技术开发有限公司 一种长春花属生物碱脂质体及其生产工艺
KR100793819B1 (ko) * 2006-06-16 2008-01-10 주식회사 펩트론 히트 블록 어셈블리 및 그를 이용한 유기 화합물 합성 반응장치
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2009059449A1 (en) * 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
JP2011513314A (ja) * 2008-02-26 2011-04-28 マリンクロッド・インコーポレイテッド 放射性医薬品加熱器
KR20140027974A (ko) * 2011-04-05 2014-03-07 버텍스 파마슈티칼스 인코포레이티드 Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물
EP3470061A1 (en) 2012-11-20 2019-04-17 Spectrum Pharmaceuticals, Inc. Improved method for the preparation of a dosage of liposome encapsulated vincristine for therapeutic use

Also Published As

Publication number Publication date
WO2014081887A1 (en) 2014-05-30
KR20150108350A (ko) 2015-09-25
IL238555A0 (en) 2015-06-30
EP2922529B1 (en) 2019-03-13
JP2016500077A (ja) 2016-01-07
EP3470061A1 (en) 2019-04-17
MX2015005992A (es) 2016-03-07
CA2891656C (en) 2021-05-04
JP6419710B2 (ja) 2018-11-07
US20150290184A1 (en) 2015-10-15
AU2013347990A1 (en) 2015-05-21
US9801874B2 (en) 2017-10-31
EP2922529A1 (en) 2015-09-30
CN104837483B (zh) 2017-09-01
ES2730405T3 (es) 2019-11-11
CN104837483A (zh) 2015-08-12
TR201908531T4 (tr) 2019-08-21
KR20200136060A (ko) 2020-12-04
IL238555B (en) 2019-05-30
RU2655964C2 (ru) 2018-05-30
CA2891656A1 (en) 2014-05-30
RU2015117412A (ru) 2017-01-10
KR102186116B1 (ko) 2020-12-03
KR102310697B1 (ko) 2021-10-12
AU2013347990B2 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
GB2501352B (en) Pump having an enclosed annular volume
GB2534761B (en) Semiconductor arrangement with active drift zone
MY168739A (en) Hypothetical reference decoder parameter syntax structure
EP2881138A4 (en) INFUSION ASSEMBLY AND METHOD FOR USING THE SAME
MY165759A (en) Pull-on diaper
HK1200384A1 (en) Pressure-regulating vial adaptors and methods
MY168276A (en) Method for Manufacturing Carbonaceous Film and Method for Manufacturing Graphite Film
GB2512553B (en) Semiconductor arrangement with active drift zone
IN2015DN03029A (ja)
EP2978692A4 (en) Capsule with messaging system
EP2847834A4 (en) LASERS WITH BEAM SHAPE MODIFICATION
MY167971A (en) Pallet container
PT2802652T (pt) Enzimas de clostridium histolyticum
EP2917825A4 (en) TRUSTWORTHY SOCIAL NETWORKS
MX2019008255A (es) Variantes de quimosina con propiedades de coagulacion de leche mejoradas.
HK1209377A1 (en) Compressble connector for an inner cannula
EP2671605A4 (en) NEEDLESS SYRINGE
IL230648A0 (en) Electric power source for an intravenous fluid heating system
HK1210457A1 (en) C-o-h compound processing for hydrogen or liquid fuel production c-o-h
PT2825633T (pt) Método para cultivar células de e. coli para alta densidade
IL221918A0 (en) Optical isolator
SG11201508217RA (en) Encapsulating magnetic fields for plasma confinement
EP2835818A4 (en) TRANSPARENT SEMICONDUCTOR COMPOUND AND PROCESS FOR PRODUCING THE SAME
EP2856137A4 (en) METHOD FOR MANUFACTURING ELECTROPHORESIS CASSETTE
EP2874640A4 (en) REDUCED GLUTATHIONE ENCAPSULATED IN LIPOSOME FOR THE TREATMENT OF CANCER, INCLUDING IN COMBINATION WITH OTHER PHARMACEUTICAL COMPOSITIONS